Secukinumab 是一种完全人源化的单克隆抗 IL-17A 抗体，是同类产品中第一个被美国食品和药物管理局批准用于治疗中度至重度斑块型银屑病的抗体。

Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.

875356-43-7

151 kDa